Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07181720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

StatusSuspended
PhasePhase 1
Started2025-09-12
View on ClinicalTrials.gov ↗

Amendment history

2026-09-09
Recruiting→Suspended Study Status, Contacts/Locations v2
Recruitment suspended: Sponsor stopped the study.
Trial statusRecruiting→Suspended
Study sitesdetails revised at 1 of 1 site
2025-09-28
Study Identification, Study Status, Contacts/Locations v1
Study title-41 characters
Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial
2025-09-12
Original filing
Chongqing Precision Biotech Co., Ltd
36 trials monitored
See 1 trial at risk
Lung Cancer
4,033 trials monitored
See 210 trials at risk
Ovarian Cancer
1,239 trials monitored
See 74 trials at risk
Cervical Cancer
853 trials monitored
See 46 trials at risk
and 2 more diseases
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Trial Details
NCT Number NCT07181720
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic Carcinoma
Enrollment 90 participants
Start Date 2025-09-12
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-11